The invention relates to a therapeutic agent for the treatment of Gunter syndrome, and more specifically to a therapeutic agent for the treatment of Gunter syndrome, which reduces the number of visits of patients suffering from Gunter syndrome to the clinic up to two times a month or less, due to the fact that this includes the first the composition for intravenous injection and the second composition for subcutaneous injection and has a clinical effect that is equivalent or even more effective than the effect achieved with standard IV injections once a week； It has a positive effect on patient compliance with the treatment regimen compared with standard therapeutic agents and treatment methods and improves the quality of life and patient comfort. The combined IV / SC injection method of the invention has a therapeutic effect that is equivalent to or even exceeds the effect achieved with a standard IV injection once a week, which allows the patient to attend the clinic less often than with standard therapy that involves visiting once a week ； where this method involves replacing the standard IV injection method once a week, at which the patient has to attend the clinic every week, with a SC injection, which, unlike the IV injection, can be done by the nurse at home a certain number of times. Thus, the present invention completely refutes the generally accepted view that the therapeutic effect of a SC injection does not exceed the therapeutic effect achieved with an IV injection. Therefore, the present invention relates to a therapeutic agent and to a method for the treatment of Gunter syndrome, which are significantly more effective compared to standard technology.Изобретение относится к терапевтическому средству для лечения синдрома Гунтера, а более конкретно к терапевтическому средству для лечения синдрома Гунтера, которое позволяет уменьшить число визитов пациентов, страдающих синдромом Гунтера, в клинику до двух раз в месяц или менее, благодаря тому, что это сре
